|Day Low/High||41.20 / 42.16|
|52 Wk Low/High||25.10 / 42.88|
Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
If we can advance without China then who the heck knows where we can go with it.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.
These favorite names in the volatile sector offer the potential for high rewards.
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
European stocks open lower Tuesday as global investors trim risky positions amid rising political tensions in the Gulf region and the ongoing turmoil in the White House.
Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates.
Roche shares gain after the company's CEO says he's 'fully dedicated' to the key U.S. market.
A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.
The WEF host country has a lot to offer to investors.
Biotech IPOs that have relationships with established drug companies will do better than those going it alone.
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.